Literature DB >> 15553345

Prenatal depression: a randomized controlled trial in the emotional health of primiparous women.

Barbara A Hayes1, Reinhold Muller.   

Abstract

The prevalence of postnatal depression (10%-15%) renders it a major public health problem not only for the depressed mother but also for the infant, who may suffer from behavioral disturbances and cognitive delays in later years. This study aimed at evaluating an educational intervention to alleviate postnatal depression and at generally measuring the prenatal and postnatal mood of primiparous women. A prospective, randomized controlled trial of an education intervention to reduce postnatal depression was conducted at three sites in Australia enrolling a total of 184 primiparous women. The intervention consisted of an information booklet on postnatal depression and an audiotape of one woman's journey through clinical postnatal depression. Mood was assessed once prenatally (12-28 weeks) and twice postnatally (8-12 weeks and 16-24 weeks) using the Scale for Assessment of Depression and Schizophrenia modified for pregnant and postnatal women (SADS-M). Demographic and social support data were also collected at enrollment. Comparisons between the control group and the intervention group revealed no differences; the educational intervention did not show any effect when women's mood was measured by the SADS-M. Overall, a general, significant, steady decrease of depressive tendencies was observed when the two postnatal assessments were compared to the prenatal measurements. Women were less depressed postnatally than prenatally. This overall improvement of mood was significant in most SADS-M items. The exceptions were discouragement, anxiety, anger, and irritability, which did not reach significance. Additional multivariate analyses revealed no relevant influence of social support or demographic variables on the changes in mood. The main results that the education intervention had no effect and women, overall, were more depressed prenatally than postnatally contributes further evidence to the view that the prenatal period is a separate entity from the postnatal period, with distinctive psychoneuro-endocrine pathways and, thus, suggesting different profiles of women's experience. This evidence indicates the necessity to screen, refer, and manage prenatal maternal mood as an entity in its own right, rather than as a window on the postnatal period.

Entities:  

Mesh:

Year:  2004        PMID: 15553345     DOI: 10.1891/rtnp.18.2.165.61277

Source DB:  PubMed          Journal:  Res Theory Nurs Pract        ISSN: 1541-6577            Impact factor:   0.688


  4 in total

1.  Reducing psychosocial and behavioral pregnancy risk factors: results of a randomized clinical trial among high-risk pregnant african american women.

Authors:  Jill G Joseph; Ayman A E El-Mohandes; Michele Kiely; M Nabil El-Khorazaty; Marie G Gantz; Allan A Johnson; Kathy S Katz; Susan M Blake; Maryann W Rossi; Siva Subramanian
Journal:  Am J Public Health       Date:  2009-04-16       Impact factor: 9.308

2.  The design, implementation and acceptability of an integrated intervention to address multiple behavioral and psychosocial risk factors among pregnant African American women.

Authors:  Kathy S Katz; Susan M Blake; Renee A Milligan; Phyllis W Sharps; Davene B White; Margaret F Rodan; Maryann Rossi; Kennan B Murray
Journal:  BMC Pregnancy Childbirth       Date:  2008-06-25       Impact factor: 3.007

3.  Antenatal psychosomatic programming to reduce postpartum depression risk and improve childbirth outcomes: a randomized controlled trial in Spain and France.

Authors:  Maria Assumpta Ortiz Collado; Marc Saez; Jérôme Favrod; Marie Hatem
Journal:  BMC Pregnancy Childbirth       Date:  2014-01-15       Impact factor: 3.007

4.  The effect of social support around pregnancy on postpartum depression among Canadian teen mothers and adult mothers in the maternity experiences survey.

Authors:  Theresa H M Kim; Jennifer A Connolly; Hala Tamim
Journal:  BMC Pregnancy Childbirth       Date:  2014-05-07       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.